A novel mutation of the MEN1 gene in a patient with multiple endocrine neoplasia type 1 and recurrent fibromyxoid sarcoma - a case report.


Journal

BMC medical genetics
ISSN: 1471-2350
Titre abrégé: BMC Med Genet
Pays: England
ID NLM: 100968552

Informations de publication

Date de publication:
29 09 2020
Historique:
received: 14 07 2020
accepted: 22 09 2020
entrez: 30 9 2020
pubmed: 1 10 2020
medline: 3 11 2020
Statut: epublish

Résumé

Multiple endocrine neoplasia type 1 (MEN1) syndrome is usually accompanied by endocrine tumors, but non-endocrine tumors can occur as well. However, the coexistence of MEN1 syndrome and malignant tumor such as low-grade fibromyxoid sarcoma has not been described in the literature. Moreover, the MEN1 gene mutations have not been identified in patients with fibromyxoid sarcoma, so far. We present a patient with a long-year endocrine follow-up due to multiple endocrine tumors. During his lifespan, he has been surgically treated for pancreatic gastrinoma, parathyroid hyperplasia, atypical pulmonary carcinoid, various benign mesenchymal, and several skin tumors (basocellular tumor, lipomas, and fibromas) which raised a high clinical suspicion of MEN1 syndrome but the patient refused genetic testing. Recently, he developed a novel malignant tumor - recurrent low-grade fibromyxoid sarcoma of the trunk and extremities with multiple subsequent operations. The patient eventually accepted the genetic testing which proved him to be a carrier of a novel mutation in the MEN1 gene. Unlike some other syndromes where a genetic mutation can predict clinical course, there is no genotype-phenotype correlation in MEN1 syndrome. Therefore, these patients require lifelong and multidisciplinary surveillance, not only for typical endocrine and benign non-endocrine tumors but also for diverse and even more malignant forms. The atypical clinical presentation should pose suspicion about new gene mutation and serve as a warning in the further follow-up.

Sections du résumé

BACKGROUND
Multiple endocrine neoplasia type 1 (MEN1) syndrome is usually accompanied by endocrine tumors, but non-endocrine tumors can occur as well. However, the coexistence of MEN1 syndrome and malignant tumor such as low-grade fibromyxoid sarcoma has not been described in the literature. Moreover, the MEN1 gene mutations have not been identified in patients with fibromyxoid sarcoma, so far.
CASE PRESENTATION
We present a patient with a long-year endocrine follow-up due to multiple endocrine tumors. During his lifespan, he has been surgically treated for pancreatic gastrinoma, parathyroid hyperplasia, atypical pulmonary carcinoid, various benign mesenchymal, and several skin tumors (basocellular tumor, lipomas, and fibromas) which raised a high clinical suspicion of MEN1 syndrome but the patient refused genetic testing. Recently, he developed a novel malignant tumor - recurrent low-grade fibromyxoid sarcoma of the trunk and extremities with multiple subsequent operations. The patient eventually accepted the genetic testing which proved him to be a carrier of a novel mutation in the MEN1 gene.
CONCLUSIONS
Unlike some other syndromes where a genetic mutation can predict clinical course, there is no genotype-phenotype correlation in MEN1 syndrome. Therefore, these patients require lifelong and multidisciplinary surveillance, not only for typical endocrine and benign non-endocrine tumors but also for diverse and even more malignant forms. The atypical clinical presentation should pose suspicion about new gene mutation and serve as a warning in the further follow-up.

Identifiants

pubmed: 32993530
doi: 10.1186/s12881-020-01129-4
pii: 10.1186/s12881-020-01129-4
pmc: PMC7526371
doi:

Substances chimiques

MEN1 protein, human 0
Proto-Oncogene Proteins 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

190

Références

Best Pract Res Clin Endocrinol Metab. 2010 Jun;24(3):355-70
pubmed: 20833329
World J Surg. 1998 Jun;22(6):581-6; discussion 586-7
pubmed: 9597932
Cancer Cell. 2019 Mar 18;35(3):441-456.e8
pubmed: 30889380
Endocr Relat Cancer. 2017 Oct;24(10):T119-T134
pubmed: 28899949
Clin Endocrinol (Oxf). 2007 Oct;67(4):613-22
pubmed: 17590169
Front Endocrinol (Lausanne). 2019 Jun 11;10:339
pubmed: 31263451
World J Surg. 2010 Feb;34(2):249-55
pubmed: 19949948
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783
pubmed: 27899578
World J Surg. 2000 Nov;24(11):1437-41
pubmed: 11038219
Nat Commun. 2018 Jul 17;9(1):2765
pubmed: 30018380

Auteurs

Maja Radman (M)

Department of Endocrinology and Diabetology, University Hospital Centre Split, Soltanska 1, Split, Croatia.
University of Split, School of Medicine, Soltanska 2, Split, Croatia.

Tanja Milicevic (T)

Department of Endocrinology and Diabetology, University Hospital Centre Split, Soltanska 1, Split, Croatia. tanja.milicevic2@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH